Our in vitro and in vivo studies suggest that anti‐CD147 ADC Mehozumab‐DM1 potently inhibits hepatocellular carcinoma, and combining CD147‐ADCs and targeted therapy may provide optimal therapeutics for patients with refractory liver cancer. This evidence concerns the gene BSG and hepatocellular carcinoma.